Kocatürk, E. Et Al. 2022. Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?. Anais Brasileiros de Dermatologia , vol.97, no.5 , 592-600.

Kocatürk, E., Başkan, E. B., Küçük, Ö. S., Özdemir, M., Örnek, S., Can, P. K., ... Haşal, E.(2022). Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?. Anais Brasileiros de Dermatologia , vol.97, no.5, 592-600.

Kocatürk, Emek Et Al. "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?," Anais Brasileiros de Dermatologia , vol.97, no.5, 592-600, 2022

Kocatürk, Emek Et Al. "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?." Anais Brasileiros de Dermatologia , vol.97, no.5, pp.592-600, 2022

Kocatürk, E. Et Al. (2022) . "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?." Anais Brasileiros de Dermatologia , vol.97, no.5, pp.592-600.

@article{article, author={Emek Kocatürk Et Al. }, title={Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?}, journal={Anais Brasileiros de Dermatologia}, year=2022, pages={592-600} }